75 related articles for article (PubMed ID: 29916804)
1. Transcriptome profiling of alphaherpesvirus-infected cells treated with the HIV-integrase inhibitor raltegravir reveals profound and specific alterations in host transcription.
Pennington MR; Grenier JK; Van de Walle GR
J Gen Virol; 2018 Aug; 99(8):1115-1128. PubMed ID: 29916804
[TBL] [Abstract][Full Text] [Related]
2. The HIV Integrase Inhibitor Raltegravir Inhibits Felid Alphaherpesvirus 1 Replication by Targeting both DNA Replication and Late Gene Expression.
Pennington MR; Voorhees IEH; Callaway HM; Dehghanpir SD; Baines JD; Parrish CR; Van de Walle GR
J Virol; 2018 Oct; 92(20):. PubMed ID: 30045987
[TBL] [Abstract][Full Text] [Related]
3. Effects of orally administered raltegravir in cats with experimentally induced ocular and respiratory feline herpesvirus-1 infection.
Spertus CB; Pennington MR; Van de Walle GR; Badanes ZI; Judd BE; Mohammed HO; Ledbetter EC
Am J Vet Res; 2019 May; 80(5):490-497. PubMed ID: 31034270
[TBL] [Abstract][Full Text] [Related]
4. A novel corneal explant model system to evaluate antiviral drugs against feline herpesvirus type 1 (FHV-1).
Pennington MR; Fort MW; Ledbetter EC; Van de Walle GR
J Gen Virol; 2016 Jun; 97(6):1414-1425. PubMed ID: 26959283
[TBL] [Abstract][Full Text] [Related]
5. The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro.
Saladini F; Giannini A; Boccuto A; Tiezzi D; Vicenti I; Zazzi M
AIDS; 2017 Oct; 31(16):2307-2309. PubMed ID: 28832412
[TBL] [Abstract][Full Text] [Related]
6. A two-week regimen of high-dose integrase inhibitors does not cause nephrotoxicity in mice.
Eadon MT; Zhang H; Skaar TC; Hato T; Dagher PC; Gupta SK; Desta Z
Antivir Chem Chemother; 2015 Apr; 24(2):72-6. PubMed ID: 26229068
[TBL] [Abstract][Full Text] [Related]
7. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
[TBL] [Abstract][Full Text] [Related]
8. A Mos1 transposase in vivo assay to screen new HIV-1 integrase inhibitors.
Cancian M; Loreto ELS
Genetica; 2018 Apr; 146(2):243-247. PubMed ID: 29352755
[TBL] [Abstract][Full Text] [Related]
9. Microbial Natural Product Alternariol 5-O-Methyl Ether Inhibits HIV-1 Integration by Blocking Nuclear Import of the Pre-Integration Complex.
Ding J; Zhao J; Yang Z; Ma L; Mi Z; Wu Y; Guo J; Zhou J; Li X; Guo Y; Peng Z; Wei T; Yu H; Zhang L; Ge M; Cen S
Viruses; 2017 May; 9(5):. PubMed ID: 28489061
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.
Calcagno A; D'Avolio A; Bonora S
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1167-76. PubMed ID: 26073580
[TBL] [Abstract][Full Text] [Related]
11. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes.
Pollicita M; Surdo M; Di Santo F; Cortese MF; Fabeni L; Fedele V; Malet I; Marcelin AG; Calvez V; Ceccherini-Silberstein F; Perno CF; Svicher V
J Antimicrob Chemother; 2014 Sep; 69(9):2412-9. PubMed ID: 24860155
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice.
Jaeckle M; Khaykin P; Haberl A; De Leuw P; Schüttfort G; Stephan C; Wolf T
Int J STD AIDS; 2016 Nov; 27(13):1170-1179. PubMed ID: 26429890
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
Buzón MJ; Massanella M; Llibre JM; Esteve A; Dahl V; Puertas MC; Gatell JM; Domingo P; Paredes R; Sharkey M; Palmer S; Stevenson M; Clotet B; Blanco J; Martinez-Picado J
Nat Med; 2010 Apr; 16(4):460-5. PubMed ID: 20228817
[TBL] [Abstract][Full Text] [Related]
15. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
16. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
Evering TH; Markowitz M
Drugs Today (Barc); 2007 Dec; 43(12):865-77. PubMed ID: 18174972
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of delivery agents used for introduction of small interfering RNAs into feline corneal cells.
Wilkes RP; Ward DA; Newkirk KM; Adams JK; Kania SA
Am J Vet Res; 2013 Feb; 74(2):243-7. PubMed ID: 23363349
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Murray JM; Emery S; Kelleher AD; Law M; Chen J; Hazuda DJ; Nguyen BY; Teppler H; Cooper DA
AIDS; 2007 Nov; 21(17):2315-21. PubMed ID: 18090280
[TBL] [Abstract][Full Text] [Related]
19. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
20. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
